Feeding Activated Bifidobacterium infantis EVC001 to Very Low Birth Weight Infants is Associated with Significant Reduction in Rates of Necrotizing Enterocolitis

Joseph Tobias; Amy Olyaei; Bryan Laraway; Brian K. Jordan; Stephanie Dickinson; Lilian G. Arroyo; Elizabeth Fialkowski; Arthur Owora; Brian Scottoline

doi:10.1101/2021.06.29.21259737

ABSTRACT

Objectives To assess the effects of Bifidobacterium infantis EVC001 administration on the rate of necrotizing enterocolitis (NEC) in preterm infants in a single Level IV NICU.

Study Design This was a retrospective observational analysis of 2 cohorts of VLBW infants (+/-B. infantis EVC001 probiotic) at OHSU from 2014 to 2020. Outcomes included NEC rates and NEC-associated mortality, including subgroup analysis of ELBW infants. Fisher’s exact test and log binomial models were used to determine differences between cohorts and risk reduction of NEC. Adjusted number needed to treat was calculated from the cohort coefficient of the model.

Results In this analysis of 483 infants, the difference in rates of NEC between cohorts was statistically significant (11.0% vs. 2.7%, P = 0.0008). The EVC001-fed cohort had a 73% risk reduction of NEC compared to the No EVC001 cohort (adjusted risk ratio 0.270, 95% CI 0.094, 0.614, P = 0.0054) resulting in an adjusted number needed to treat of 12.4 (95% CI 10.0, 23.5) for B. infantis EVC001. There was no NEC-related mortality in the EVC001-fed cohort, yielding statistically significant differences from the No EVC001 cohort overall (0% vs. 2.7%, P = 0.0274) and the ELBW subgroup (0% vs. 5.6%, P = 0.0468).

Conclusion(s) B. infantis EVC001 feeding was associated with a significant reduction in the rate of NEC and NEC-related mortality in an observational study of 483 VLBW infants. B. infantis EVC001 supplementation may be considered safe and effective for reducing morbidity and mortality in the NICU.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: BS and AO received grant funding from Evolve BioSystems for this work; BS is an unpaid member of the Infant Advisory Board for Evolve BioSystems; and BS is a research member of The NEC Society, a non-profit NEC support and research organization

Funding Statement

This research was supported by grants from Evolve BioSystems to BS and AO

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approved by the Oregon Health & Science University IRB (#20336)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Conflict of interest disclosure: Dr. Scottoline serves as a member of the Infant Health Advisory Board of Evolve BioSystems, Inc. and receives no compensation for this role. The study sponsors (Evolve BioSystems, Inc.) provided limited guidance with regard to study design and the decision to submit the manuscript for publication.
Data sharing: Data will be made available on request.
Financial disclosure: This work was supported by grants from Evolve BioSystems, Inc.
Prior presentation: Portions of the data contained in this paper were presented in poster or oral presentation form at the Pediatric Academic Society’s 2021 Annual Meeting, the 2021 NEC Society Virtual Sessions, and Cool Topics 2021.